ArticleCureus2024
Radio Electric Asymmetric Conveyer (REAC) Biomodulation for Chronic Pain and Functional Improvement in Rheumatoid Arthritis, Lipedema, and Fibromyalgia: A Case Study on Anti-inflammatory, Circulatory, and Metabolic Optimization.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- REAC RGN-AR treatment modulates adipogenic differentiation in adipose tissue-derived stem cells.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report explores the use of radio electric asymmetric conveyor (REAC) technology for chronic pain management, functional limitations, and metabolic dysfunction in a 67-year-old female with rheumatoid arthritis, advanced lipedema, and fibromyalgia. The patient underwent three REAC protocols: Anti-cellulite treatment (ACT), circulatory optimization (CO), and metabolic optimization (MO), each targeting distinct pathophysiological aspects. The ACT protocol primarily addressed chronic inflammation contributing to pain and tissue dysfunction associated with lipedema. The CO protocol enhanced joint mobility by improving systemic and local blood flow, relieving joint stiffness due to rheumatoid arthritis. The MO protocol focused on metabolic restoration to counter chronic fatigue linked to lipedema and fibromyalgia. SF-12 results showed a significant improvement in physical health index (50.88% to 68.16%) and mental health index (58.38% to 86.40%). Depression, anxiety and stress scale - 21 (DASS-21) scores indicated a decrease in the depression index (47.62% to 23.81%) and stress index (57.14% to 42.86%), with anxiety remaining stable at 23.81%. This case underscores REAC technology's potential as a non-invasive, multifaceted intervention addressing underlying inflammation, circulatory impairment, and metabolic dysregulation in complex chronic conditions, offering a valuable alternative to conventional treatments. Following treatment, the patient reported substantial reductions in pain and physical discomfort, increased mobility, and enhanced energy and emotional well-being. Improvements began after ACT, with decreased pain and increased ease in daily activities. CO further supported joint mobility, allowing tasks like walking and stair-climbing with less strain. MO led to greater overall vitality and mood stability, enabling a more active lifestyle. No significant adverse effects were reported. This case underscores REAC technology's potential as a non-invasive, multifaceted intervention addressing the underlying inflammation, circulatory impairment, and metabolic dysregulation in complex chronic conditions, offering a valuable alternative to conventional treatments. Further research could clarify REAC's broader applications in similar multifactorial cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.